Savara (SVRA) Research & Development (2010 - 2026)
Savara's (SVRA) quarterly Research & Development came in at $23.4 million in Q1 2026, up 22.13% year-on-year from $19.2 million in Q1 2025, and up 11.94% on a QoQ basis from $20.9 million in Q4 2025.
Savara (SVRA) Research & Development (2010 - 2026) Analysis & Trends
Savara (SVRA) has 17 years of Research & Development data on file, last reported at $23.4 million in Q1 2026.
- On a quarterly basis, Research & Development rose 22.13% year-over-year to $23.4 million in Q1 2026; TTM through Mar 2026 was $85.6 million, a 6.55% increase from a year earlier, with the FY2025 full-year figure at $81.4 million, up 4.33% from the prior year.
- Research & Development for Q1 2026 stood at $23.4 million, up from $20.9 million in the prior quarter.
- Over the last five years, Research & Development for SVRA reached as high as $23.4 million in Q1 2026 and fell as low as $5.7 million in Q1 2022.
- Historically, Research & Development has averaged $15.0 million across 5 years, with a median of $16.8 million in 2024.
- Across the five-year window, Research & Development retreated 25.1% in 2022 and soared 97.7% in 2024, its largest moves.
- Year by year, Research & Development stood at $7.6 million in 2022, then soared by 67.14% to $12.7 million in 2023, then jumped by 82.76% to $23.3 million in 2024, then retreated by 10.27% to $20.9 million in 2025, then rose by 11.94% to $23.4 million in 2026.
- Per Business Quant data, the three most recent Research & Development figures were $23.4 million in Q1 2026, $20.9 million in Q4 2025, and $20.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 541.22 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -2.31 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.37 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 343.97 Mn |
| 10 | Savara | 1.24 Bn | 1.24 Bn | - | 23.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.40 Mn |
| Dec 31, 2025 | 20.90 Mn |
| Sep 30, 2025 | 20.59 Mn |
| Jun 30, 2025 | 20.75 Mn |
| Mar 31, 2025 | 19.16 Mn |
| Dec 31, 2024 | 23.29 Mn |
| Sep 30, 2024 | 20.31 Mn |
| Jun 30, 2024 | 17.62 Mn |
| Mar 31, 2024 | 16.81 Mn |
| Dec 31, 2023 | 12.75 Mn |
| Sep 30, 2023 | 13.87 Mn |
| Jun 30, 2023 | 8.91 Mn |
| Mar 31, 2023 | 8.74 Mn |
| Dec 31, 2022 | 7.63 Mn |
| Sep 30, 2022 | 8.15 Mn |
| Jun 30, 2022 | 6.42 Mn |
| Mar 31, 2022 | 5.68 Mn |
| Dec 31, 2021 | 7.62 Mn |
| Sep 30, 2021 | 6.53 Mn |
| Jun 30, 2021 | 7.25 Mn |